Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement #Biotechnology #CRDL #CRDL.CA #Cannabis #Cardiolrx #Investing #NASDAQ #TSX

Toronto, Ontario--(Newsfile Corp. - October 20, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that on October 19, 2023, it received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq"), stating that the Company is not in compliance with the minimum bid...


http://dlvr.it/SxlG40

Comments

Popular posts from this blog

ICEBERG Financial Announces New Fintech Product and Pre-Launch Institutional Contract #Banking #FinancialServices

Coelacanth Announces Q3 2023 Financial and Operating Results #CEI.CA #CEI.V #CEIEF #Earnings #Investing #OTC #OTCMarkets #OTCStocks #Oil #OilAndGas #QuarterlyResults #Results #SmallCaps #TSXV

Aurora Solar Technologies Corporate Update #AACTF #ACU.CA #ACU.V #AlternativeEnergy #AuroraSolarTech #CleanEnergy #CorporateUpdate #Energy #Investing #OTC #OTCMarkets #OTCStocks #RenewableEnergy #SmallCaps #Solar #TSXV